Silicon-Based Hydrogen Pills Reduce Asthma Symptoms in Mice
- Authors
- Honoka Takeuchi, Marumi Taya, Sana Takashima, Nobumasa Hino, Chihaya Kakinuma, Yuki Kobayashi, Hikaru Kobayashi, Shinsaku Nakagawa
- Journal
- Biomedical Journal
- Year
- 2026
- DOI
- 10.1016/j.bj.2026.101017
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Allergic Bronchial Asthma
- Body System
- Respiratory
TL;DR
A dietary silicon-based hydrogen-generating agent reduced allergic airway inflammation in asthmatic mice, but the findings remain preclinical.
Key Finding
A silicon-based hydrogen-generating agent significantly reduced airway inflammation and immune cell infiltration in mice with allergic asthma, suggesting it may be an effective delivery method for hydrogen therapy.
Summary
Researchers tested a silicon-based material that generates hydrogen gas in the digestive system as a potential treatment for allergic asthma in mice. When mice with asthma-like symptoms received this material in their diet, it reduced the number of immune cells (eosinophils) in their airways, decreased inflammation in lung tissue, and lowered levels of inflammatory proteins and antibodies associated with allergic reactions.
Practical Takeaway
This early-stage mouse study suggests silicon-based hydrogen generators may help manage allergic asthma by reducing inflammation, but much more research is needed before any conclusions can be drawn for human use. The findings are limited to animal models and do not yet indicate whether this approach would be safe or effective in people with asthma.
Abstract
Background: Hydrogen therapy, which involves the intake of hydrogen as an antioxidant, has been reported to be effective against various oxidative stress-related diseases. However, current methods of hydrogen administration present various problems. Therefore, new methods that allow for the safe and sustained delivery of high doses of hydrogen are needed. Si-based agents offer a promising solution because they can easily and continuously generate large amounts of hydrogen in the digestive tract. Asthma is characterized by chronic airway inflammation, and allergic bronchial asthma-its most readily recognized phenotype-is suspected to be related to oxidative stress. We investigated the effects of Si-based agents on allergic bronchial asthma. Material and methods: Allergic bronchial asthma was induced in female C57BL/6N mice by epicutaneous sensitization and inhalation challenge with ovalbumin. Bronchial asthma was assessed by cell counts in bronchoalveolar lavage fluid (BALF) and lung histopathological analysis. mRNA expression levels of cytokines and chemokine in lung tissue and total IgE concentration in serum were measured. Results: The administration in the diet of this Si-based agent to a model mouse of allergic bronchial asthma significantly suppressed eosinophil counts in the BALF and reduced inflammatory cell infiltration in the lungs. In addition, the expressions of interleukins 5, and 13 and C-C motif chemokine 11 in lung tissue tended to decreased in the Si group compared with those in the control group. We examined the timing of administration of Si-based agents and found that Si-based agents worked during the sensitization and elicitation phases and tended to decrease the total IgE concentration in serum. Conclusions: Si-based agents are effective against allergic bronchial asthma and may serve as superior materials for hydrogen therapy. We anticipate that our study will provide valuable insights into the mechanisms of Si-based agents against type I allergy and facilitate their clinical application in the future.